ÂÜÀòÂÒÂ×

Alun Bermingham is an experienced biopharmaceutical executive, currently serving as Senior Vice President and Head of Platform at Totus Medicines, where responsibilities include the execution and evolution of the OmniDEL platform. Previously, as Vice President, Platform Screening and Biology, Alun built and oversaw the OmniDEL screening and biology teams. Alun's extensive background also includes senior roles at REVOLUTION Medicines and Novartis Institutes for BioMedical Research, focusing on lead discovery and screening teams. Additional experience encompasses research positions at Memorial Sloan-Kettering Cancer Center, the National Cancer Institute, and AstraZeneca. Alun Bermingham holds a PhD in Enzymology and an MSc in Bioinformatics, both from The University of Manchester.